Clinical Information

Gram-negative bacilli (GNB) with acquired carbapenemases have disseminated worldwide, rendering them a global threat. The therapeutic armamentarium for infections caused by carbapenem-resistant Enterobacterales (CRE) is limited, and CRE infections have been associated with significant mortality. Enterobacterales harboring Klebsiella pneumoniae carbapenemase are endemic in some regions of the United States, and although still sporadic, GNB harboring New Delhi metallo-beta-lactamase have been reported from several states. Timely detection of these carbapenemases (along with emerging carbapenemases such as OXA-48 and VIM) is important. Detection is challenging since isolates may have only borderline reductions in susceptibility to carbapenems, and carbapenem resistance may be mediated by mechanisms other than carbapenemases (eg, AmpC or extended-spectrum beta-lactamase with decreased membrane permeability). While molecular methods are confirmatory, testing may not be immediately available and may be limited by the number of targets assayed. The Carba NP test is preferred over the mCIM (modified carbapenem inactivation method) test due to faster turnaround time.

If an isolate is suspected to possess KPC or NDM carbapenemase (eg, due to local epidemiology), Carbapenem Resistance Genes, Molecular Detection, PCR, Varies (CARBI) may be preferred over the Carba NP test.